Log in
NASDAQ:GLPG

Galapagos Competitors

$125.25
+0.58 (+0.47 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$123.90
Now: $125.25
$125.61
50-Day Range
$114.53
MA: $128.63
$148.25
52-Week Range
$112.00
Now: $125.25
$274.03
Volume90,570 shs
Average Volume159,622 shs
Market Capitalization$8.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.79

Competitors

Galapagos (NASDAQ:GLPG) Vs. ALXN, BGNE, RPRX, GMAB, CTLT, and HZNP

Should you be buying GLPG stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Galapagos, including Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), Catalent (CTLT), and Horizon Therapeutics Public (HZNP).

Galapagos (NASDAQ:GLPG) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Profitability

This table compares Galapagos and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos8.13%8.24%3.82%
Alexion Pharmaceuticals16.32%23.16%14.76%

Earnings & Valuation

This table compares Galapagos and Alexion Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion8.16$167.83 million$5.4622.94
Alexion Pharmaceuticals$4.99 billion5.38$2.40 billion$9.7412.59

Alexion Pharmaceuticals has higher revenue and earnings than Galapagos. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Galapagos has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Galapagos and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210402.13
Alexion Pharmaceuticals081512.71

Galapagos presently has a consensus price target of $180.1538, indicating a potential upside of 43.84%. Alexion Pharmaceuticals has a consensus price target of $145.25, indicating a potential upside of 18.47%. Given Galapagos' higher possible upside, research analysts clearly believe Galapagos is more favorable than Alexion Pharmaceuticals.

Institutional and Insider Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 84.2% of Alexion Pharmaceuticals shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Alexion Pharmaceuticals beats Galapagos on 13 of the 15 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Galapagos and BeiGene's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion8.16$167.83 million$5.4622.94
BeiGene$428.21 million58.05$-948,630,000.00($15.80)-17.33

Galapagos has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Galapagos and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos8.13%8.24%3.82%
BeiGene-569.22%-56.81%-39.93%

Institutional & Insider Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 52.6% of BeiGene shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Galapagos has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Galapagos and BeiGene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210402.13
BeiGene15402.30

Galapagos presently has a consensus price target of $180.1538, suggesting a potential upside of 43.84%. BeiGene has a consensus price target of $237.7875, suggesting a potential downside of 13.15%. Given Galapagos' higher possible upside, equities analysts clearly believe Galapagos is more favorable than BeiGene.

Summary

Galapagos beats BeiGene on 7 of the 13 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Galapagos (NASDAQ:GLPG) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional and Insider Ownership

36.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 11.6% of Galapagos shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by company insiders. Comparatively, 2.9% of Galapagos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Royalty Pharma and Galapagos, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Galapagos210402.13

Royalty Pharma currently has a consensus target price of $51.8750, suggesting a potential upside of 29.04%. Galapagos has a consensus target price of $180.1538, suggesting a potential upside of 43.84%. Given Galapagos' higher possible upside, analysts clearly believe Galapagos is more favorable than Royalty Pharma.

Valuation & Earnings

This table compares Royalty Pharma and Galapagos' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Galapagos$1.00 billion8.16$167.83 million$5.4622.94

Galapagos has higher revenue and earnings than Royalty Pharma.

Profitability

This table compares Royalty Pharma and Galapagos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Galapagos8.13%8.24%3.82%

Summary

Galapagos beats Royalty Pharma on 6 of the 8 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Risk & Volatility

Galapagos has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Institutional and Insider Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 5.8% of Genmab A/S shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Galapagos and Genmab A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210402.13
Genmab A/S25702.36

Galapagos presently has a consensus price target of $180.1538, suggesting a potential upside of 43.84%. Genmab A/S has a consensus price target of $38.8571, suggesting a potential upside of 7.82%. Given Galapagos' higher probable upside, analysts plainly believe Galapagos is more favorable than Genmab A/S.

Profitability

This table compares Galapagos and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos8.13%8.24%3.82%
Genmab A/S50.99%36.69%33.24%

Earnings & Valuation

This table compares Galapagos and Genmab A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion8.16$167.83 million$5.4622.94
Genmab A/S$804.57 million29.34$324.68 million$0.5170.67

Genmab A/S has lower revenue, but higher earnings than Galapagos. Galapagos is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Genmab A/S beats Galapagos on 9 of the 14 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Catalent (NYSE:CTLT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Galapagos and Catalent, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210402.13
Catalent01702.88

Galapagos currently has a consensus target price of $180.1538, indicating a potential upside of 43.84%. Catalent has a consensus target price of $105.50, indicating a potential upside of 5.71%. Given Galapagos' higher possible upside, equities analysts plainly believe Galapagos is more favorable than Catalent.

Insider & Institutional Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 91.0% of Catalent shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 1.0% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Galapagos and Catalent's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion8.16$167.83 million$5.4622.94
Catalent$3.09 billion5.31$173 million$1.8853.09

Catalent has higher revenue and earnings than Galapagos. Galapagos is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Galapagos has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Profitability

This table compares Galapagos and Catalent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos8.13%8.24%3.82%
Catalent9.25%14.20%4.83%

Summary

Catalent beats Galapagos on 10 of the 14 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Insider and Institutional Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 89.2% of Horizon Therapeutics Public shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Galapagos and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos8.13%8.24%3.82%
Horizon Therapeutics Public43.55%25.66%14.19%

Analyst Ratings

This is a summary of recent ratings and target prices for Galapagos and Horizon Therapeutics Public, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210402.13
Horizon Therapeutics Public011002.91

Galapagos presently has a consensus price target of $180.1538, indicating a potential upside of 43.84%. Horizon Therapeutics Public has a consensus price target of $81.1667, indicating a potential upside of 15.87%. Given Galapagos' higher probable upside, analysts clearly believe Galapagos is more favorable than Horizon Therapeutics Public.

Volatility and Risk

Galapagos has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Valuation & Earnings

This table compares Galapagos and Horizon Therapeutics Public's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion8.16$167.83 million$5.4622.94
Horizon Therapeutics Public$1.30 billion11.89$573.02 million$1.9436.11

Horizon Therapeutics Public has higher revenue and earnings than Galapagos. Galapagos is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Summary

Horizon Therapeutics Public beats Galapagos on 12 of the 14 factors compared between the two stocks.


Galapagos Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.1$122.61+1.0%$26.83 billion$4.99 billion28.65Decrease in Short Interest
BeiGene logo
BGNE
BeiGene
1.3$273.78+3.8%$24.86 billion$428.21 million-13.55Analyst Revision
Royalty Pharma logo
RPRX
Royalty Pharma
1.8$40.20+0.4%$24.41 billionN/A0.00
GMAB
Genmab A/S
1.2$36.04+1.4%$23.61 billion$804.57 million27.94
Catalent logo
CTLT
Catalent
1.7$99.80+3.5%$16.44 billion$3.09 billion63.57
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.2$70.05+0.1%$15.46 billion$1.30 billion19.14Analyst Downgrade
Increase in Short Interest
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$31.03+5.2%$14.64 billion$3.07 billion-54.44Analyst Report
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$123.02+1.4%$14.29 billion$219.75 million-15.71
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$77.04+1.4%$13.99 billion$1.70 billion17.63
Grifols logo
GRFS
Grifols
1.5$18.66+0.9%$12.83 billion$5.71 billion20.73
MyoKardia logo
MYOK
MyoKardia
0.9$224.91+0.0%$11.99 billion$33.56 million-39.88
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.0$225.00+0.8%$11.31 billion$3.34 million-29.22Decrease in Short Interest
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.4$64.06+1.6%$10.62 billion$2.32 billion42.15
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
2.0$134.49+2.5%$10.61 billion$380.83 million-19.16
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
2.0$9.61+1.4%$10.50 billion$16.89 billion4.16
Mylan logo
MYL
Mylan
1.9$15.86+0.0%$8.59 billion$11.50 billion29.92High Trading Volume
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.6$53.84+0.5%$8.56 billion$339.08 million-31.30
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.8$158.48+1.2%$8.37 billion$14.98 million-19.30
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$144.31+0.8%$8.04 billion$2.16 billion45.52
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$50.27+2.2%$7.03 billion$1.12 billion104.73Unusual Options Activity
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.3$114.69+0.3%$7.00 billion$103.71 million-21.97
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.2$68.20+0.9%$6.98 billion$168.80 million-272.80Earnings Announcement
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$19.31+1.9%$6.86 billion$8.60 billion-3.54
Perrigo logo
PRGO
Perrigo
2.4$47.75+0.8%$6.52 billion$4.84 billion27.44
United Therapeutics logo
UTHR
United Therapeutics
1.4$137.77+1.3%$6.12 billion$1.45 billion14.14
Zai Lab logo
ZLAB
Zai Lab
1.2$104.96+0.6%$6.10 billion$12.98 million-34.64Decrease in Short Interest
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$22.39+1.8%$5.83 billion$182.24 million-19.47
BBIO
BridgeBio Pharma
1.4$46.44+4.8%$5.69 billion$40.56 million-13.62
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.6$163.63+0.5%$5.54 billion$26.52 million-15.25Analyst Upgrade
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.9$98.76+1.1%$5.50 billion$66.51 million18.22Decrease in Short Interest
Allakos logo
ALLK
Allakos
1.0$103.63+2.1%$5.44 billionN/A-37.82Decrease in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.2$88.48+10.9%$5.30 billionN/A-7.21Insider Buying
TPTX
Turning Point Therapeutics
1.7$104.37+1.2%$5.03 billionN/A-28.06Decrease in Short Interest
SDGR
Schrödinger
1.5$67.65+10.4%$4.70 billion$85.54 million0.00Analyst Upgrade
Insider Selling
High Trading Volume
Unusual Options Activity
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$62.24+1.4%$4.25 billion$306.98 million-8.87
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$79.67+3.8%$4.22 billion$1.11 billion25.62Heavy News Reporting
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$31.06+3.6%$4.14 billion$204.89 million-38.83
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$77.97+2.3%$4.06 billion$6.87 million-6.61
Insmed logo
INSM
Insmed
0.9$39.18+0.3%$3.99 billion$136.47 million-15.07Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.28+2.1%$3.96 billion$36.13 million-85.49
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$30.09+0.8%$3.96 billion$150,000.00-14.47
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.7$125.44+0.5%$3.89 billion$311.33 million-72.93Decrease in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$64.68+0.2%$3.76 billion$806.43 million-9.16
FibroGen logo
FGEN
FibroGen
1.6$40.19+0.8%$3.66 billion$256.58 million-15.40Analyst Downgrade
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.5$47.85+5.1%$3.62 billionN/A-6.45Analyst Report
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.4$61.67+0.7%$3.51 billion$25 million-12.33
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.2$85.09+4.6%$3.29 billion$26.69 million-32.11Decrease in Short Interest
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.5$34.08+1.2%$3.11 billion$34.51 million-32.77Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.8$44.03+1.0%$3.05 billion$117.91 million-8.93Decrease in Short Interest
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.7$16.53+1.4%$2.97 billion$114.62 million-6.67
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.